Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Pediatric Immunology Service, |
RCV000681577 | SCV000693925 | likely pathogenic | Histiocytic medullary reticulosis; Atypical severe combined immunodeficiency due to complete RAG1/2 deficiency; Recombinase activating gene 2 deficiency; Inborn error of immunity | 2018-03-06 | criteria provided, single submitter | research | |
Genomic Research Center, |
RCV000626255 | SCV000746908 | uncertain significance | Histiocytic medullary reticulosis | 2017-12-18 | criteria provided, single submitter | clinical testing | |
Green |
RCV001815003 | SCV002061918 | uncertain significance | Immunodeficiency 104 | criteria provided, single submitter | clinical testing | This variant has been reported in compound heterozygous state along with a termination variant in an affected patient (Asai E et al).Functional studies revealed that the variant exhibited 59% of activity when compared to wild type. The variant is predicted to be damaging by both SIFT and PolyPhen2. The residue is conserved across species. The amino acid change p.Arg73His in RAG2 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. The p.Arg73His variant is novel (not in any individuals) in 1000 Genomes and is present in 0.0007% individuals in gnomAD database. For the above reasons it has been classified as Uncertain Significance. | |
Labcorp Genetics |
RCV002530946 | SCV003439727 | pathogenic | Combined immunodeficiency with skin granulomas; Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-positive | 2023-12-25 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 73 of the RAG2 protein (p.Arg73His). This variant is present in population databases (rs762407838, gnomAD 0.008%). This missense change has been observed in individuals with severe combined immunodeficiency (PMID: 21131235, 26515615). ClinVar contains an entry for this variant (Variation ID: 496620). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt RAG2 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects RAG2 function (PMID: 26515615, 29772310). This variant disrupts the p.Arg73 amino acid residue in RAG2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 20603253, 24481607, 26476733; Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV003471947 | SCV004200536 | likely pathogenic | Combined immunodeficiency with skin granulomas | 2024-01-17 | criteria provided, single submitter | clinical testing |